Before and After: MDC Website Redesign Comparison of the Minimum Deposit Casinos website before and after the comprehensive redesign. The updated site features streamlined navigation, enhanced functionality, a modern aesthetic, updated logo, and improved user-centric features. WATERFORD, Ireland, July 15, 2024 (GLOBE NEWSWIRE) — Minimum Deposit Casinos (MDC), a premier online resource for casino enthusiasts, […]
Pakistan
Minimum Deposit Casinos Announces Completion of Full Website Revamp
Before and After: MDC Website Redesign Comparison of the Minimum Deposit Casinos website before and after the comprehensive redesign. The updated site features streamlined navigation, enhanced functionality, a modern aesthetic, updated logo, and improved user-centric features. WATERFORD, Ireland, July 15, 2024 (GLOBE NEWSWIRE) — Minimum Deposit Casinos (MDC), a premier online resource for casino enthusiasts, […]
BASF Environmental Catalyst and Metal Solutions breaks ground on new green hydrogen investment in Budenheim, Germany
Groundbreaking of new green hydrogen production facility in Budenheim, Germany Pictured left to right: Dr. Günter Krummel, Gesellschafter Trigona FCC; André Semann, CFO Budenheim; Meaghan McGuire, Head of Strategic Marketing, Hydrogen, BASF ECMS; Tim Ingle, SVP Precious Metal Services and Recycling, BASF ECMS; Saeed Alerasool, SVP R&D and Application, BASF ECMS; Daniel Malko, Head of […]
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe. […]
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe. […]